Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Gomez Arteaga on an Investigation of Orca-T Vs PTCy-Based HCT in Acute Leukemia and MDS

February 24th 2024

Alexandra Gomez Arteaga, MD, discusses a retrospective study of Orca-T vs post-transplant cyclophosphamide in acute leukemia and MDS.

Dr Bertaina on T-allo10 Infusion in Young Patients With Hematologic Malignancies

February 24th 2024

Alice Bertaina MD, PhD, discusses T-allo10 infusion post–aβdepleted-HSCT in young patients with hematologic malignancies.

Belumosudil Plus Ruxolitinib Displays Activity in Steroid-Refractory/-Dependent cGVHD

February 23rd 2024

Belumosudil plus ruxolitinib elicited responses with acceptable tolerability in patients with chronic graft-vs-host disease.

Dr Auletta on the Impact of Post-Transplant Cyclophosphamide in Hematologic Malignancies

February 23rd 2024

Jeffery Auletta, MD, discusses the impact of post-transplant cyclophosphamide in hematologic malignancies.

Dr Hamilton on HRQOL Differences With Gilteritinib Vs Placebo in Post-Transplant FLT3-ITD+ AML

February 23rd 2024

Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.

Dr Lee on 3-Year Follow-Up Data From the ROCKstar Trial of Belumosudil in cGVHD

February 23rd 2024

Stephanie Lee, MD, MPH, discusses 3-year follow-up data from the phase 3 ROCKstar Study of belumosudil in cGVHD.

Immune Engager Therapies Demonstrate Promise Following Relapse on Ide-Cel in Multiple Myeloma

February 23rd 2024

Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.

Concomitant Azoles Does Not Affect Clinical Outcomes With Ruxolitinib in Acute GVHD

February 23rd 2024

Concomitant azoles did not negatively affect efficacy with ruxolitinib or best available therapy in patients with acute graft-versus-host disease.

Ruxolitinib Plus Belumosudil Boosts Responses in Chronic GVHD

February 23rd 2024

Ruxolitinib and belumosudil demonstrated a beneficial ORR, indicating synergistic effects in targeting multiple inflammatory pathways in chronic GVHD.

Ruxolitinib Cream Is Tolerable and Effective in Cutaneous GVHD

February 23rd 2024

A cream formulation of ruxolitinib was deemed safe and effective compared with placebo in patients with cutaneous graft-versus-host disease.

The Future of Allo-HSCT and Cellular Therapies

February 23rd 2024

Speculation on anticipated innovations in allo-HSCT and cellular therapy technologies in the future.

Investigational Allo-HSCT for Advanced Hematologic Malignancies

February 23rd 2024

The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.

Acalabrutinib/Axi-Cel Generates Preliminary Responses in Relapsed/Refractory B-Cell Lymphoma

February 23rd 2024

Early data seen with acalabrutinib plus axi-cel indicate the combination’s feasibility as bridging therapy in relapsed/refractory B-cell lymphoma.

IO-202 Receives FDA Orphan Drug Designation for CMML

February 22nd 2024

The FDA has granted IO-202 an orphan drug designation for patients with chronic myelomonocytic leukemia.

Future Landscape of Chronic GVHD

February 22nd 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz share their predictions for the next 3 to 5 years in chronic GVHD management. The panel anticipates advancements in earlier treatment, potential elimination of frontline corticosteroids, and a shift towards preventive strategies and personalized medicine.

Emerging Agents in GVHD: Axatilimab

February 22nd 2024

The panel reviews axatilimab, an emerging agent for chronic GVHD under clinical studies. The experts explore findings from the Agave-201 study, highlighting potential challenges of intravenous administration and axatilimab’s unique mechanisms.

FDA Grants Orphan Drug Designation to Ocifisertib for Acute Myeloid Leukemia

February 21st 2024

The FDA granted an orphan drug designation to ocifisertib for use as a potential therapeutic option in patients with acute myeloid leukemia.

ESA Treatment Selection in MDS

February 20th 2024

Clinical insights on selecting appropriate erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

Unmet Needs and Adverse Event Management for Patients With Lower-Risk MDS and Symptomatic Anemia

February 20th 2024

Hematologist-oncologists address adverse event management and discuss the unmet needs of patients with lower-risk MDS and symptomatic anemia.

Additional Data Updates from ASH 2023

February 20th 2024

Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.